Chairman, CEO and President of Penumbra Inc (30-Year Financial, Insider Trades) Adam Elsesser (insider trades) sold 8,000 shares of PEN on 07/11/2019 at an average price of $171.84 a share. The total sale was $1.4 million.
Penumbra Inc designs, develops, manufactures and markets medical devices. The products of the company address ischemic stroke, hemorrhagic stroke and vascular conditions that can be treated through thrombectomy and embolization procedures. Penumbra Inc has a market cap of $6 billion; its shares were traded at around $172.73 with a P/E ratio of 575.79 and P/S ratio of 13.56. GuruFocus has detected 2 severe warning signs with Penumbra Inc. .
CEO Recent Trades:
- Chairman, CEO and President Adam Elsesser sold 8,000 shares of PEN stock on 07/11/2019 at the average price of $171.84. The price of the stock has increased by 0.52% since.
CFO Recent Trades:
- CFO and Head of Strategy Sridhar Kosaraju sold 5,000 shares of PEN stock on 07/01/2019 at the average price of $159.96. The price of the stock has increased by 7.98% since.
Directors and Officers Recent Trades:
- Director Bridget O'rourke sold 175 shares of PEN stock on 07/01/2019 at the average price of $160.67. The price of the stock has increased by 7.51% since.
For the complete insider trading history of PEN, click here
.
